[Market Feature] HEM Pharma Hits Record High on News of Leading Production in Amway's New Project
HEM Pharma is showing strong performance in early trading.
As of 9:03 a.m. on December 2, HEM Pharma was trading at 53,600 won, up 8.28% (4,100 won) from the previous day. At one point, it rose to 54,500 won, marking a new 52-week high.
Investor sentiment has been boosted by news that the company will lead production in a new probiotics development project spearheaded by Amway's Nutrilite brand. This project is a new global product that maximizes gut health benefits by combining HEM Pharma's newly developed strains with plant-derived ingredients from Amway's farms.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
HEM Pharma has completed all technical verification procedures between Korea and the United States, including an on-site inspection of its Sejong plant and a review of test reports, in collaboration with Amway's global headquarters. Having secured technical feasibility and supply chain reliability at the pilot stage, the company expects to accelerate its global market expansion going forward.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.